Steffen Wolk

Dr. Steffen Wolk


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2015 in International Journal of Surgery
Verified
Journal Article
Closed access
SWSteffen Wolk
Steffen Wolk
MDMarius Distler
Marius Distler
SKStephan Kersting
Stephan Kersting
JWJürgen Weitz
Jürgen Weitz
HSHans-Detlev Saeger
Hans-Detlev Saeger
RGRobert Grützmann
Robert Grützmann
For minor pancreatic resection such as enucleation (PE) and central pancreatectomy (CP) comparative data are rare. These techniques provide parenchyma-sparing alternatives to major resections (e.g. pancreaticoduodenectomy) for neuroendocrine tumors, cystic tumors or metastases. This study retrospectively compares the morbidity and mortality of both techniques, with special regard to the formation of postoperative pancreatic fistulas (POPF). Between December 1996 and November 2013 the postoperative events and clinical outcomes of 17 patients after pancreatic enucleation and 26 patients after central pancreatectomy were retrospectively analyzed from a prospectively collected database. Perioperative mortality was 0% in both groups. There was no significant difference in the overall peri-operative morbidity (CP 80.8% vs. PE 82.4%). The major cause of the high morbidity was the formation of a POPF with 26.9% of the patients after CP and 35.3% after PE. Univariate analysis showed a BMI over 30 kg/m(2) in the CP group to be an independent risk factor. Additional minor complications, e.g. urinary tract infection, pleural effusion, etc. furthermore contributed to the perioperative morbidity. PE and central CP are feasible techniques for selected patients, but the indications are limited. Morbidity after these resections is high with the major cause being the development of a POPF.

21 February 2017 in Trials
Verified
Journal Article
Open access
PDF file
SWSteffen Wolk
Steffen Wolk
TMTheresa Meißner
Theresa Meißner
SLSebastian Linke
Sebastian Linke
BMBenjamin Müssle
Benjamin Müssle
AWAnn Wierick
Ann Wierick
TWThilo Welsch
Thilo Welsch
Enhanced recovery after surgery (ERAS) programs are aimed at minimizing postoperative stress and accelerating postoperative recovery by implementing multiple perioperative principles. “Early mobilization” is one such principle, but the quality of assessment and monitoring is poor, and evidence of improved outcome is lacking. Activity trackers allow precise monitoring and automatic feedback to the patients to enhance their motivation for early mobilization. The aim of the study is to monitor and increase the postoperative mobilization of patients by giving them continuous automatic feedback in the form of a step count using activity-tracking wristbands. Patients undergoing elective open and laparoscopic surgery of the colon, rectum, stomach, pancreas, and liver for any indication will be included. Further inclusion criteria are age between 18 and 75 years, American Society of Anesthesiologists Physical Status class less than IV, and a signed informed consent form. Patients will be stratified into two subgroups, laparoscopic and open surgery, and will be randomized 1:1 for automatic feedback of their step count using an activity tracker wristband. The control group will have no automatic feedback. The sample size (n = 30 patients in each of the four groups, overall n = 120) is calculated on the basis of an assumed difference in step count of 250 steps daily (intervention group versus control group). The primary study endpoint is the average step count during the first 5 postoperative days; secondary endpoints are the percentage of patients in the two groups who master the predefined mobilization (step count) targets, assessment of additional activity data obtained from the devices, assessment of preoperative mobility, length of hospital and intensive care unit stays, number of patients who receive physiotherapy, 30-day mortality, and overall 30-day morbidity. Early mobilization is a key element of ERAS. However, enhanced early mobilization is difficult to define, to assess objectively, and to implement in clinical practice. Consequently, there is a discrepancy between ERAS targets and actual practice, especially in patients undergoing major visceral surgery. This study is the first randomized controlled trial investigating the use and feasibility of activity tracking to monitor and enhance postoperative early mobilization. ClinicalTrials.gov identifier: NCT02834338 . Registered on 15 June 2016.

18 April 2023 in Antioxidants
Verified
Journal Article
Open access
PDF file
BHBianca Hamann
Bianca Hamann
AKAnna Klimova
Anna Klimova
FKFelicia Klotz
Felicia Klotz
FFFrieda Frank
Frieda Frank
CJChristian Jänichen
Christian Jänichen
CRChristian Reeps
Christian Reeps
Red blood cells are found within the abdominal aortic aneurysm (AAA), in the intraluminal thrombus (ILT), and in neovessels. Hemolysis promotes aortic degeneration, e.g., by heme-induced reactive oxygen species formation. To reduce its toxicity, hemoglobin is endocytosed by the CD163 receptor and heme is degraded by heme oxygenase-1 (HO-1). A soluble form (sCD163) is discussed as an inflammatory biomarker representing the activation of monocytes and macrophages. HO-1 and NAD(P)H quinone dehydrogenase 1 (NQO1) are antioxidant genes that are induced by the Nrf2 transcription factor, but their regulation in AAA is only poorly understood. The aim of the present study was to analyze linkages between CD163, Nrf2, HO-1, and NQO1 and to clarify if plasma sCD163 has diagnostic and risk stratification potential. Soluble CD163 was 1.3-fold (p = 0.015) higher in AAA compared to patients without arterial disease. The difference remained significant after adjusting for age and sex. sCD163 correlated with the thickness of the ILT (rs = 0.26; p = 0.02) but not with the AAA diameter or volume. A high aneurysmal CD163 mRNA was connected to increases in NQO1, HMOX1, and Nrf2 mRNA. Further studies are needed to analyze the modulation of the CD163/HO-1/NQO1 pathway with the overall goal of minimizing the detrimental effects of hemolysis.

23 March 2021 in Langenbeck's Archives of Surgery
Verified
Journal Article
Open access
PDF file
SWSteffen Wolk
Steffen Wolk
MDMarius Distler
Marius Distler
CRChristoph Radosa
Christoph Radosa
FEFlorian Ehehalt
Florian Ehehalt
HBHendrik Bergert
Hendrik Bergert
SLStefan Ludwig
Stefan Ludwig
Purpose: Visceral and renal artery aneurysms (VAA, RAA) are very rare pathologies. Both surgical and endovascular therapies are discussed as therapeutic options for ruptured and non-ruptured aneurysm repair; we describe our experience in the open and endovascular management of these entities. Methods: Retrospective database analysis of 60 treated VAA and RAA in 59 patients between 1994 and 2020. Outcome data was descriptively analyzed. Results: Thirty-seven aneurysms were surgically treated and 23 interventionally. In the total study cohort, we observed a mortality of 1.7% and a morbidity of 18.6%. One major complication occurred. The morbidity was higher after surgical repair in ruptured and non-ruptured cases. The mean aneurysm diameter was 30.5 ± 15.6 mm. Patients with hepatic or pancreaticoduodenal artery aneurysms presented more often in the stage of rupture, without differences in aneurysm size. The length of hospital stay after endovascular repair was significantly shorter compared to open surgical treatment (7.2 ± 6.9 days versus 11.8 ± 6.7 days, p = 0.014), but only in elective cases. Primary technical success was significantly better in patients that underwent surgical repair in an intention to treat analysis (100% versus 79.3%). The mean follow-up of the cohort was 53.5 months (range 3–207 months). Conclusion: Elective endovascular therapy and open surgery of VAA and RAA are safe procedures with a good periprocedural and long-term outcome. Surgical revascularization showed a better primary technical success but was associated with longer length of hospital stays.

19 February 2022 in Langenbeck's Archives of Surgery
Verified
Journal Article
Open access
PDF file
SWSteffen Wolk
Steffen Wolk
MKMarvin Kapalla
Marvin Kapalla
SLStefan Ludwig
Stefan Ludwig
CRChristoph Radosa
Christoph Radosa
RHRalf-Thorsten Hoffmann
Ralf-Thorsten Hoffmann
CRChristian Reeps
Christian Reeps
Purpose: Chronic mesenteric ischemia (CMI) is a rare but life-threatening disease. This study reviewed outcomes in patients treated surgically for CMI by open treatment (OT) and endovascular treatment (ET), analyzing risk factors for endovascular failure. Methods: Clinical data for 36 patients treated for CMI from 2007 to 2017 were retrospectively analyzed. The study’s primary endpoint was symptom-free survival. The secondary endpoint was the primary technical success for endovascular and open surgical treatments. Risk factors for endovascular failure were identified by using univariate analysis. Results: Patients were analyzed as treated: 21 patients (58.3%) in the ET and 15 (41.6%) in the OT group. Overall, 20 patients (56%) presented with abdominal angina, 9 (25%) with rest pain, and 7 (19%) without symptoms. An ET was initially attempted in 31 patients (86.1%). The conversion rate from ET to OT was 32.3%, which resulted in a primary technical success of 67.6% in ET and 100% in OT. Six patients from the ET group (19.3%) required surgical revision due to restenosis. One-year (OT 91.6% vs. ET 96.8%; n.s.) and three-year primary patency (OT 91.6% vs. ET 80.6%; n.s.) as well as 3-year symptom-free survival did not differ between the groups (OT 62.5% vs. ET 69.4%; n.s). Overall, in-hospital mortality was 2.8% (n = 1), which was not statistically different between the groups (OT 6% vs. ET 0%; n.s.). High-grade stenosis of the superior mesenteric artery tended to be associated with higher technical failure (P = 0.06). Conclusions: ET showed a comparable perioperative outcome with higher technical failure. OT was distinguished by excellent early and late technical success.

18 July 2023 in Journal of the American Heart Association
Verified
Journal Article
Open access
AHAnja Hofmann
Anja Hofmann
YKYazan Khorzom
Yazan Khorzom
AKAnna Klimova
Anna Klimova
SWSteffen Wolk
Steffen Wolk
ABAlbert Busch
Albert Busch
CRChristian Reeps
Christian Reeps
Background: Indication for prophylactic surgical abdominal aortic aneurysm (AAA) repair depends on the maximal aortic diameter. The lectin‐like oxidized low‐density lipoprotein receptor‐1 (LOX‐1) is the major receptor for uptake of oxidized low‐density lipoprotein cholesterol and is implicated in atherosclerosis. A soluble form of LOX‐1 (sLOX‐1) has been discussed as a novel biomarker in coronary artery disease and stroke. Herein, we assessed the regulation of aortic LOX‐1 as well as the diagnostic and risk stratification potential of sLOX‐1 in patients with AAA. Methods and Results: Serum sLOX‐1 was assessed in a case–control study in AAA (n=104) and peripheral artery disease (n=104). sLOX‐1 was not statistically different between AAA and peripheral artery disease but was higher in AAA (β=1.28, P =0.04) after adjusting for age, atherosclerosis, type 2 diabetes, prescription of statins, β‐blockers, ACE inhibitors, and therapeutic anticoagulation. sLOX‐1 was not associated with the aortic diameter, AAA volume, or the thickness of the intraluminal thrombus. Aortic LOX‐1 mRNA expression tended to be higher in AAA when compared with disease, and expression was positively associated with cleaved caspase‐3, smooth muscle actin, collagen, and macrophage content. Conclusions: In AAA, sLOX‐1 was differently affected by age, cardiometabolic diseases, and corresponding medical therapies. Comparison with nonatherosclerotic disease would be beneficial to further elucidate the diagnostic potential of sLOX‐1, although it was not useful for risk stratification. Aneurysmal LOX‐1 mRNA expression was increased and positively associated with smooth muscle cells and collagen content, suggesting that LOX‐1 is eventually not deleterious in human AAA and could counteract AAA rupture.